CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia

Read full text
Authors: Saubia Fathima, Lior Rokach, Muhammad Yousuf, Priyansh Faldu, Ali Khalid A. Alsugair, Clifford Michael Csizmar, Merry Nakhleh, Abhishek Avinash Mangaonkar, Animesh Pardanani, Luca Lanino, Alessia Campagna, Giulia Maggioni
+8 more Noushin Rahnamay Farnoud, Raajit K. Rampal, Kaaren K. Reichard, Rong Lucy He, Naseema Gangat, Mrinal M. Patnaik, Matteo G. Della Porta, Ayalew Tefferi
Cited by: 1
References: 21

Abstract

Contemporary risk models in chronic myelomonocytic leukemia (CMML) focus on the prognostic relevance of individual rather than concurrent mutations. In the current study of 605 Mayo Clinic patients with CMML, we applied machine-learning algorithms in order to examine the influence of cooperative mutational interactions on blast transformation (BT). A hierarchical clustering algorithm was developed and tailored for patient stratification using survival outcomes and co-occurrence of genomic alterations. Five molecular clusters were identified with 3-year blast BT rates ranging from 0% to 100% (AUC at 3 years 0.78). A subsequent Cox regression analysis confirmed independent detrimental impact of specific mutations or their combinations including NPM1 (HR 26.7; p < 0.01), "NRAS + SETBP1" (HR 12.6; p < 0.01), "ASXL1 + BCOR" (HR 8.4; p < 0.01), "ASXL1 + RUNX1" (HR 2.2, p < 0.01), JAK2 (HR 2.1; p < 0.01), and "ASXL1 + TET2" (HR 1.7; p = 0.02) while "PHF6+wild-type ASXL1" (HR 5.61e-10; p < 0.01) had a favorable impact. Furthermore, compared to NPM1 wild-type cases, NPM1-mutated patients were less likely to have co-occurring mutations involving ASXL1 (0% vs. 43%, p < 0.01), RUNX1 (0% vs. 17%, p = 0.02), and SRSF2 (7% vs. 39%, p < 0.01) and were more likely DNMT3A (71% vs. 7%, p < 0.01). The prognostic relevance of "NRAS + SETBP1", "ASXL1 + RUNX1", NPM1 and BCOR was validated in an external cohort from Italy (N = 501). Taken together, these observations highlight i) the possibility of prognostic interaction of mutations in CMML that should be considered in the development of future risk models and ii) the distinct genotypic and prognostic characteristics of NPM1-mutated CMML.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
11 April 2026
Language
EN